Ro5-4864 Stats & Data

• Identity/mechanism: Ro5-4864 has high affinity for the mitochondrial 18 kDa translocator protein (TSPO; historically “peripheral benzodiazepine receptor”) and shows minimal/atypical activity at central high‑affinity benzodiazepine sites on GABA_A receptors; flumazenil only antagonizes classical benzodiazepine site effects and should not be relied on to reverse Ro5-4864 toxicity.

• Proconvulsant potential: Multiple rodent studies show Ro5-4864 facilitates or directly induces seizures (including audiogenic seizures) in a dose‑dependent manner; a TSPO antagonist (PK11195) can block some of these effects. This strongly cautions against high doses or redosing.

• Do not use for benzodiazepine withdrawal: Because its primary action is at TSPO rather than the GABA_A benzodiazepine site, Ro5-4864 will not substitute for benzodiazepines in dependence/withdrawal and could worsen seizure risk during withdrawal. Standard withdrawal management targets GABA_A modulation with established agents under medical care.

• Dosing precision: Effects have a narrow and inconsistent window; sub‑milligram errors can dramatically change outcomes. Use a 1 mg‑accurate scale and/or volumetric dosing; label solutions clearly to avoid dosing mistakes.

• Route of administration: Oral is the only route with any community familiarity; smoking/vaping/injection are strongly discouraged due to unknown human PK, likely thermal degradation, and increased harm (local tissue reaction risk with non‑oral routes). Absence of reliable inhalation data makes potency unpredictable.

• Overdose/AE management: Expect poor response to flumazenil; supportive care with airway protection and standard anticonvulsants for seizures is the likely approach in clinical settings. Bring full substance information to emergency services immediately.

• Redosing risk: Anxiety, inner restlessness, tremor, and delayed‑onset seizures have been reported anecdotally with redoses ≥ ~5 mg; wait at least 2 hours before any cautious reassessment to avoid stacking. Community reports also document mis‑sold batches (e.g., as diclazepam).

• Contamination/mislabelling: 4‑Chlorodiazepam appeared in Europe’s Early Warning System in 2016 and, like other NPS benzodiazepines, may surface unexpectedly in markets. Use trusted drug checking when available; benzo‑adulteration of opioids has been common in many locales.

• Co‑use with opioids: Mixtures of opioids and benzodiazepine‑related drugs are frequent in unregulated markets and complicate overdose; avoid co‑use and carry naloxone if opioids might be involved (note naloxone will not reverse benzodiazepine‑like components).

• Populations at elevated risk: History of seizures/epilepsy, recent head injury, active benzodiazepine taper/withdrawal, and pregnancy (TSPO is involved in steroidogenesis) warrant extra caution or avoidance.

• Set/setting and safety: Avoid driving and hazardous tasks for at least 12–24 h after dosing; ensure a trusted, sober sitter if experimenting with micro‑doses due to paradoxical agitation risk.